FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to methods of self-specific T-cell vaccine production. Self-specific T-cell vaccine for disseminated sclerosis treatment includes attenuated T-cells which are reactive relative to one or several epitopes, yet SEQ ID NOS: 1-6 contain these epitopes. Invention is intended for treatment of autoimmune diseases, such as disseminated sclerosis or rheumatoid arthritis using self-specific T-cell vaccines. Besides, invention provides diagnostics of diseases associated with T-cells. Advantage of this invention implies that it can be applied for production of T-call vaccines with heterogenous gene VR-Dp-JR to take into consideration clonal shift if self-reactive T-cells.
EFFECT: method has improved efficiency.
10 cl, 7 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLULAR VACCINE FOR CEREBROSPINAL SCLEROSIS TREATMENT | 1998 |
|
RU2209633C2 |
| METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
| METHOD FOR PRODUCTION OF POLYCLONAL T-CELL VACCINE USEFUL IN TREATMENT OF IMMUNOLOGICAL DISORDERS | 2004 |
|
RU2277422C2 |
| METHOD FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERE | 2011 |
|
RU2635537C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| METHOD FOR PRODUCING MODEL IMMORTALIZED CELL LINE CONTAINING RECONSTRUCTED B-CELL RECEPTOR OF NON-HODGKIN LYMPHOMAS | 2018 |
|
RU2720912C1 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| COMPOSITIONS AND METHODS USED FOR ASSESSING CYTOTOXICITY OF SINGLE CELLS | 2009 |
|
RU2532228C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES MEDIATED BY REGULATORY T-CELLS | 2017 |
|
RU2727900C2 |
